Johnson & Johnson Company Profile (NYSE:JNJ)

About Johnson & Johnson

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: JNJ
  • CUSIP: 47816010
Key Metrics:
  • Previous Close: $118.08
  • 50 Day Moving Average: $114.45
  • 200 Day Moving Average: $117.02
  • 52-Week Range: $2,720,531,000.00 - $102.97
  • Trailing P/E Ratio: 20.04
  • Foreward P/E Ratio: 16.11
  • P/E Growth: 2.86
  • Market Cap: $323.36B
  • Outstanding Shares: 2,720,531,000
  • Beta: 0.74
  • Net Margins: 22.78%
  • Return on Equity: 25.61%
  • Return on Assets: 13.40%
  • Debt-to-Equity Ratio: 0.32%
  • Current Ratio: 2.73%
  • Quick Ratio: 2.36%
Additional Links:
Companies Related to Johnson & Johnson:

Analyst Ratings

Consensus Ratings for Johnson & Johnson (NYSE:JNJ) (?)
Ratings Breakdown: 1 Sell Rating, 11 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.32)
Consensus Price Target: $122.40 (2.98% upside)

Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
DateFirmActionRatingPrice TargetDetails
1/26/2017Wells Fargo & CompanyDowngradeOutperform -> Market Perform$112.28 -> $112.80View Rating Details
1/25/2017RBC Capital MarketsLower Price TargetOutperform$133.00 -> $128.00View Rating Details
1/25/2017Royal Bank Of CanadaLower Price TargetOutperform$133.00 -> $128.00View Rating Details
1/25/2017Goldman Sachs Group, Inc. (The)Lower Price TargetNeutral$120.00 -> $115.00View Rating Details
1/20/2017Jefferies Group LLCBoost Price TargetHold$110.00 -> $120.00View Rating Details
12/20/2016Credit Suisse GroupReiterated RatingHoldView Rating Details
11/29/2016Barclays PLCDowngradeOverweight -> Equal Weight$130.00 -> $125.00View Rating Details
11/28/2016Bank of America CorpReiterated RatingHold$126.00View Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00View Rating Details
10/21/2016ArgusReiterated RatingBuy$145.00View Rating Details
9/11/2016Leerink SwannReiterated RatingBuyView Rating Details
9/7/2016BTIG ResearchReiterated RatingNeutralView Rating Details
8/19/2016Deutsche Bank AGReiterated RatingBuy$142.00View Rating Details
7/20/2016BMO Capital MarketsReiterated RatingOutperform$132.00View Rating Details
5/20/2016Raymond James Financial, Inc.Reiterated RatingOutperform$120.00View Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00View Rating Details
5/19/2016Morgan StanleyReiterated RatingHoldView Rating Details
4/20/2016Piper Jaffray CompaniesBoost Price TargetNeutral$105.00 -> $106.00View Rating Details
4/17/2016J P Morgan Chase & CoReiterated RatingHoldView Rating Details
1/27/2016Independent Research GmbHSet Price TargetNeutral$108.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$95.00View Rating Details
10/15/2015S&P Equity ResearchReiterated RatingBuy$120.00View Rating Details
8/25/2015Cowen and CompanyReiterated RatingOutperform$114.00View Rating Details
(Data available from 2/19/2015 forward)


Earnings History for Johnson & Johnson (NYSE:JNJ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.66$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.40 billionViewListenView Earnings Details
1/20/2015Q414$1.26$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.43$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
Current Year EPS Consensus Estimate: $7.04 EPS
Next Year EPS Consensus Estimate: $7.38 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.60$1.67$1.64
Q2 20163$1.64$1.68$1.66
Q3 20162$1.63$1.71$1.67
Q4 20161$1.55$1.55$1.55
Q1 20171$1.71$1.71$1.71
Q2 20171$1.81$1.81$1.81
Q3 20171$1.75$1.75$1.75
Q4 20171$1.72$1.72$1.72
Q1 20181$1.86$1.86$1.86
Q2 20181$1.97$1.97$1.97
Q3 20181$1.91$1.91$1.91
(Data provided by Zacks Investment Research)


Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
Annual Dividend:$3.20
Dividend Yield:2.69%
Dividend Growth:6.70% (3 Year Average)
Payout Ratio:54.42% (Based on Trailing 12 Months of Earnings)
45.45% (Based on Current Year Consensus EPS Estimate)
43.36% (Based on Next Year Consensus EPS Estimate)
Track Record:54 Years of Consecutive Dividend Growth

Dividend History for Johnson & Johnson (NYSE:JNJ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Johnson & Johnson (NYSE:JNJ)
Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 65.30%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.25View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Johnson & Johnson (NYSE:JNJ)
News IconJohnson & Johnson's half-hearted switch from plastic to paper cotton buds isn't good enough (NYSE:JNJ) - February 18 at 5:25 PM
News IconBaby Lotion generic - Buy breck baby lotion, Johnson johnson baby lotion sale, Buy playtex baby magic lotion (NYSE:JNJ) - February 18 at 5:25 PM logoJohnson & Johnson's Ethicon buys Torax Medical (NYSE:JNJ) - February 18 at 5:21 PM logoExclusive: Following Up Akebia, Johnson & Johnson's Research And License Agreement (NYSE:JNJ) - February 17 at 4:18 PM logoPfizer's Xeljanz Combo Comparable to AbbVie's Humira (NYSE:JNJ) - February 17 at 4:18 PM logo​Ethicon to acquire competitor (NYSE:JNJ) - February 17 at 4:18 PM logoNo Joke: Johnson & Johnson Could Grow Sales by 5% (or More) Annually Over the Next Decade - Nasdaq (NYSE:JNJ) - February 17 at 8:33 AM logoNo Joke: Johnson & Johnson Could Grow Sales by 5% (or More ... - Motley Fool (NYSE:JNJ) - February 17 at 8:33 AM logoHurry Up and Grab Some Johnson & Johnson Before the Stock Bursts Even More - (NYSE:JNJ) - February 17 at 8:33 AM
News IconActelion Pharmaceuticals Ltd - Johnson & Johnson publishes prospectus for Actelion tender offer (NYSE:JNJ) - February 16 at 10:48 PM
News IconPress Release: Johnson & Johnson publishes prospectus for Actelion tender offer (NYSE:JNJ) - February 16 at 5:45 PM
News IconHere’s why Johnson & Johnson won the bidding for Actelion — and Sanofi didn’t (NYSE:JNJ) - February 16 at 5:45 PM logoTop 4 Dividend Stocks for 2017 (JNJ, CVX) (NYSE:JNJ) - February 16 at 5:45 PM
News IconJohnson & Johnson Named a 2017 Fortune's Most Admired Company (NYSE:JNJ) - February 16 at 5:45 PM logoJohnson & Johnson Is Not Cheap, And It Never Will Be (NYSE:JNJ) - February 16 at 5:45 PM logoWarren Buffett's billion dollar bet on Apple stock (NYSE:JNJ) - February 16 at 5:45 PM logoActelion says J&J's $280 per share offer to start March 3 (NYSE:JNJ) - February 16 at 5:45 PM logoHow Sanofi lost out to J&J in $30 bln battle for Actelion (NYSE:JNJ) - February 16 at 5:45 PM logoHow Sanofi lost out to J&J in $30 billion battle for Actelion (NYSE:JNJ) - February 16 at 5:45 PM logoSanofi Backtracked on Actelion Offer Price Amid J&J Talks (NYSE:JNJ) - February 16 at 5:45 PM logo[video]Hurry Up and Grab Some Johnson & Johnson Before the Stock Bursts Even More (NYSE:JNJ) - February 16 at 5:45 PM logoJohnson & Johnson (JNJ) Stock Breaks Higher (NYSE:JNJ) - February 16 at 3:55 PM logoNo Joke: Johnson & Johnson Could Grow Sales by 5% (or More) Annually Over the Next Decade (NYSE:JNJ) - February 15 at 9:24 AM
News IconDay Two link with Johnson & Johnson on personalised microbiome analysis for diabetes nutrition (NYSE:JNJ) - February 15 at 5:34 AM logoJohnson & Johnson : to Participate in Barclays Global Healthcare Conference (NYSE:JNJ) - February 15 at 12:33 AM
News IconJohnson & Johnson (JNJ) Shares Sold by Covington Capital Management (NYSE:JNJ) - February 15 at 12:33 AM
News IconThe Johnson & Johnson (JNJ) Position Increased by the Nwam LLC (NYSE:JNJ) - February 15 at 12:33 AM
News IconJohnson & Johnson (JNJ) Stake Cut by JP Marvel Investment Advisors LLC (NYSE:JNJ) - February 15 at 12:33 AM
News IconCalvin Johnson once ruptured Charles Tillman's tricep (NYSE:JNJ) - February 14 at 7:32 PM logoJohnson & Johnson : Honored in Fast Company's Top Ten Most Innovative Biotech Companies (NYSE:JNJ) - February 14 at 7:32 PM
News IconJohnson & Johnson to Stop Selling Plastic Cotton Swabs for the Best Reason Ever (NYSE:JNJ) - February 14 at 7:32 PM logoJohnson & Johnson: Strong And Steady Dividend Champ (NYSE:JNJ) - February 14 at 7:32 PM logo6:13 am Johnson & Johnson announces positive results from the full data read out for two Phase III studies evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen t (NYSE:JNJ) - February 14 at 7:32 PM logoJohnson & Johnson to Participate in Barclays Global Healthcare Conference (NYSE:JNJ) - February 14 at 7:32 PM logo3 Stocks You Don’t Have to Babysit (NYSE:JNJ) - February 14 at 6:29 PM logoFourth Talcum Powder Lawsuit Heads to Trial in Missouri Ovarian Cancer Litigation, Bernstein Liebhard LLP Reports (NYSE:JNJ) - February 14 at 5:14 AM logoJohnson & Johnson nips ecological doomsday scenario in the (cotton) bud (NYSE:JNJ) - February 14 at 5:13 AM logoActelion, being bought by J&J, says FY profit rose 26 pct (NYSE:JNJ) - February 14 at 5:13 AM logoActelion, being bought by J&J, says FY core net income rose 27 pct (NYSE:JNJ) - February 14 at 5:13 AM
News IconAkebia Licenses Janssen HIF-Targeting Portfolio (NYSE:JNJ) - February 14 at 12:09 AM logoInteresting March Stock Options for JNJ (NYSE:JNJ) - February 14 at 12:09 AM logoAkebia Licenses Portfolio of Novel HIF Compounds from Johnson & Johnson Innovation (NYSE:JNJ) - February 13 at 7:08 PM logoAkebia Therapeutics (AKBA) Licenses HIF Compounds from Johnson & Johnson (JNJ) (NYSE:JNJ) - February 13 at 7:08 PM
News IconJohnson & Johnson ditch plastic cotton buds to save oceans (NYSE:JNJ) - February 13 at 7:08 PM
News IconAkebia in HIF compounds play with Johnson & Johnson (NYSE:JNJ) - February 13 at 7:08 PM logoJohnson & Johnson: What Will The 55th Dividend Increase Be? (NYSE:JNJ) - February 13 at 7:08 PM
News IconNo more plastic in cotton buds: Johnson & Johnson confirm they will make stems from a different material after campaign to banish them from the sea (NYSE:JNJ) - February 13 at 7:08 PM logo4 Companies Affected by Strength of the US Dollar (NYSE:JNJ) - February 13 at 7:08 PM logoNo Drugs for Back Pain, New Guidelines Say (NYSE:JNJ) - February 13 at 7:08 PM logo4 Companies That Will Benefit From Trump's Repatriation Tax Reform (NYSE:JNJ) - February 13 at 7:08 PM


What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Tuesday, January 3rd. Shareholders of record on Tuesday, February 28th will be given a dividend of $0.80 per share on Tuesday, March 14th. This represents a $3.20 annualized dividend and a yield of 2.69%. The ex-dividend date of this dividend is Friday, February 24th.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?

19 equities research analysts have issued 1-year target prices for Johnson & Johnson's shares. Their forecasts range from $94.00 to $145.00. On average, they anticipate Johnson & Johnson's share price to reach $122.40 in the next year.

When will Johnson & Johnson announce their earnings?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, April, 18th 2017.

What are analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • According to Zacks Investment Research, "J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, potential biosimilar competition and lower HCV revenues.  While Pfizer’s launch of biosimilar Remicade creates some uncertainty regarding the segment’s sales growth in 2017, we believe that the impact may be manageable. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Estimates have remained mostly stable lately ahead of the Q4 earnings results. J&J has a positive record of earnings surprises in recent quarters. J&J's shares have surpassed that of large-cap pharma industry in 2016. However, headwinds persist in the form of generics and biosimilar competition and pricing pressure." (1/9/2017)

  • Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)

  • Morgan Stanley analysts commented, "We need more evidence of execution to raise our numbers, but in a more bullish scenario the Consumer margin opportunity and growth acceleration in both segments could be worth ~9% upside to our current 2020 EPS estimate, and represent ~13% upside to J&J’s SOTP given the higher consumer multiple." (5/19/2016)

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (5.64%), FMR LLC (1.21%), Barrow Hanley Mewhinney & Strauss LLC (0.44%), Franklin Resources Inc. (0.28%), Dimensional Fund Advisors LP (0.24%) and AQR Capital Management LLC (0.23%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Aberdeen Asset Management PLC UK, Federated Investors Inc. PA, Tweedy Browne Co. LLC, TCW Group Inc., Barrow Hanley Mewhinney & Strauss LLC, Westwood Holdings Group Inc. and RidgeWorth Capital Management LLC. Company insiders that have sold Johnson & Johnson stock in the last year include Dominic J Caruso, Gary J Pruden, Paulus Stoffels and Ronald A Kapusta.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Russell Investments Group Ltd., Asset Management One Co. Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Renaissance Technologies LLC, Elkfork Partners LLC, Equity Investment Corp Acquisition Inc and Genovese Burford & Brothers Wealth & Retirement Plan Management LLC.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Johnson & Johnson stock cost?

One share of Johnson & Johnson stock can currently be purchased for approximately $118.86.

Johnson & Johnson (NYSE:JNJ) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Earnings History Chart

Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)

Dividend History Chart

Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Last Updated on 2/19/2017 by Staff